Anthracycline-containing chemotherapy causes long-term impairment of mitochondrial respiration and increased reactive oxygen species release in skeletal muscle
Gilles Gouspillou, Celena Scheede-Bergdahl, Sally Spendiff, Madhusudanarao Vuda, Brian Meehan, Heather Mlynarski, Elodie Archer-Lahlou, Nicolas Sgarioto, Fennigje M Purves-Smith, Yana Konokhova, Janusz Rak, Stéphanie Chevalier, Tanja Taivassalo, Russell T Hepple, R Thomas Jagoe, Gilles Gouspillou, Celena Scheede-Bergdahl, Sally Spendiff, Madhusudanarao Vuda, Brian Meehan, Heather Mlynarski, Elodie Archer-Lahlou, Nicolas Sgarioto, Fennigje M Purves-Smith, Yana Konokhova, Janusz Rak, Stéphanie Chevalier, Tanja Taivassalo, Russell T Hepple, R Thomas Jagoe
Abstract
Anticancer treatments for childhood acute lymphoblastic leukaemia (ALL) are highly effective but are now implicated in causing impaired muscle function in long-term survivors. However, no comprehensive assessment of skeletal muscle mitochondrial functions in long-term survivors has been performed and the presence of persistent chemotherapy-induced skeletal muscle mitochondrial dysfunction remains a strong possibility. Non-tumour-bearing mice were treated with two drugs that have been used frequently in ALL treatment (doxorubicin and dexamethasone) for up to 4 cycles at 3-week intervals and euthanized 3 months after the 4th cycle. Treated animals had impaired growth and lower muscle mass as well as reduced mitochondrial respiration and increased reactive oxygen species production per unit oxygen consumption. Mitochondrial DNA content and protein levels of key mitochondrial membrane proteins and markers of mitochondrial biogenesis were unchanged, but protein levels of Parkin were reduced. This suggests a novel pattern of chemotherapy-induced mitochondrial dysfunction in skeletal muscle that persists because of an acquired defect in mitophagy signaling. The results could explain the observed functional impairments in adult survivors of childhood ALL and may also be relevant to long-term survivors of other cancers treated with similar regimes.
Figures
References
- Siegel R., Naishadham D. & Jemal A. Cancer statistics, 2012. CA Cancer J Clin 62, 10–29 (2012).
- Zuelzer W. W. Implications of long-term survival in acute stem cell leukemia of childhood treated with composite cyclical therapy. Blood 24, 477–494 (1964).
- Hudson M. M. et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 309, 2371–2381 (2013).
- Scheede-Bergdahl C. & Jagoe R. T. After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood. Front Pharmacol 4, 49 (2013).
- Pui C.-H. & Evans W. E. Treatment of acute lymphoblastic leukemia. N Engl J Med 354, 166–178 (2006).
- Ewer M. S. & Ewer S. M. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 7, 564–575 (2010).
- Peters J. H., Gordon G. R., Kashiwase D. & Acton E. M. Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin. Cancer Chemother Pharmacol 7, 65–69 (1981).
- Octavia Y. et al. Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52, 1213–1225 (2012).
- Serrano J., Palmeira C. M., Kuehl D. W. & Wallace K. B. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim Biophys Acta 1411, 201–205 (1999).
- Adachi K. et al. A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. Biochem Biophys Res Commun 195, 945–951 (1993).
- Lebrecht D., Setzer B., Ketelsen U. P., Haberstroh J. & Walker U. A. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 108, 2423–2429 (2003).
- Lebrecht D. et al. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Brit J Pharmacol 151, 771–778 (2007).
- Lebrecht D., Kokkori A., Ketelsen U.-P., Setzer B. & Walker U. A. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol 207, 436–444 (2005).
- Ito H. et al. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 87, 4275–4279 (1990).
- Yamada K., Sugiyama S., Kosaka K., Hayakawa M. & Ozawa T. Early appearance of age-associated deterioration in mitochondrial function of diaphragm and heart in rats treated with doxorubicin. Exp Gerontol 30, 581–593 (1995).
- Gilliam L. A. A. et al. Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes. Am J Physiol Cell Physiol 302, C195–C202 (2012).
- Gilliam L. A. A. et al. Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. J Appl Physiol 107, 1935–1942 (2009).
- Batchelor T. T., Taylor L. P., Thaler H. T., Posner J. B. & DeAngelis L. M. Steroid myopathy in cancer patients. Neurology 48, 1234–1238 (1997).
- Mitsui T. et al. Chronic corticosteroid administration causes mitochondrial dysfunction in skeletal muscle. J Neurol 249, 1004–1009 (2002).
- Kuznetsov A. et al. Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells. Nat Protocol 3, 965–976 (2008).
- Gouspillou G. et al. Increased sensitivity to mitochondrial permeability transition and myonuclear translocation of endonuclease G in atrophied muscle of physically active older humans. The FASEB Journal 28, 1621–1633 (2014).
- Samuels D. C., Schon E. A. & Chinnery P. F. Two direct repeats cause most human mtDNA deletions. Trends Genet 20, 393–398 (2004).
- He L. et al. Detection and quantification of mitochondrial DNA deletions in individual cells by real-time PCR. Nucleic Acids Res 30, e68 (2002).
- Mordente A., Meucci E., Silvestrini A., Martorana G. E. & Giardina B. Anthracyclines and mitochondria. Adv Exp Med Biol 942, 385–419 (2012).
- Palikaras K. & Tavernarakis N. Mitochondrial homeostasis: The interplay between mitophagy and mitochondrial biogenesis. Exp Gerontol (2014).
- Geisler S. et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nature 12, 119–131 (2010).
- Sun Y., Vashisht A. A., Tchieu J., Wohlschlegel J. A. & Dreier L. Voltage-dependent Anion Channels (VDACs) Recruit Parkin to Defective Mitochondria to Promote Mitochondrial Autophagy. J Biol Chem 287, 40652–40660 (2012).
- Grady R. M. et al. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90, 729–738 (1997).
- Trifunovic A. et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429, 417–423 (2004).
- Jansson J., Hsu Y.-C., Kuzin I. I., Campbell A. & Mullen C. A. Acute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects. Leuk Res 35, 800–807 (2011).
- Picard M. et al. Mitochondrial structure and function are disrupted by standard isolation methods. PLoS ONE 6, e18317 (2011).
- Anderson E. J. et al. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol 54, 1891–1898 (2009).
- Kuznetsov A. V. et al. Application of inhibitor titrations for the detection of oxidative phosphorylation defects in saponin-skinned muscle fibers of patients with mitochondrial diseases. Biochim Biophys Acta 1360, 142–150 (1997).
- Picard M., Ritchie D., Thomas M. M., Wright K. J. & Hepple R. T. Alterations in intrinsic mitochondrial function with aging are fiber type-specific and do not explain differential atrophy between muscles. Aging Cell 10, 1047–1055 (2011).
- Gouspillou G. & Hepple R. T. Facts and controversies in our understanding of how caloric restriction impacts the mitochondrion. Exp Gerontol 48, 1075–1084 (2013).
- Caffin F. et al. Altered skeletal muscle mitochondrial biogenesis but improved endurance capacity in trained OPA1-deficient mice. J Physiol 591, 6017–6037 (2013).
- Nielsen J. et al. Subcellular localization-dependent decrements in skeletal muscle glycogen and mitochondria content following short-term disuse in young and old men. Am J Physiol Endocrinol Metab 299, E1053–E1060 (2010).
- Wagatsuma A. et al. Mitochondrial adaptations in skeletal muscle to hindlimb unloading. Mol Cell Biochem 350, 1–11 (2010).
- Min K. et al. Mitochondrial-targeted antioxidants protect skeletal muscle against immobilization-induced muscle atrophy. J Appl Physiol 111, 1459–1466 (2011).
- Yan L. J., Levine R. L. & Sohal R. S. Oxidative damage during aging targets mitochondrial aconitase. Proc Natl Acad Sci USA 94, 11168–11172 (1997).
- Yan L. J. & Sohal R. S. Mitochondrial adenine nucleotide translocase is modified oxidatively during aging. Proc Natl Acad Sci USA 95, 12896–12901 (1998).
- Hammerling B. C. & Gustafsson Ã. B. Mitochondrial quality control in the myocardium: cooperation between protein degradation and mitophagy. J Mol Cell Cardiol 75, 122–130 (2014).
- Picard M. et al. Mitochondrial functional impairment with aging is exaggerated in isolated mitochondria compared to permeabilized myofibers. Aging Cell 9, 1032–1046 (2010).
- Old S. L. & Johnson M. A. Methods of microphotometric assay of succinate dehydrogenase and cytochrome c oxidase activities for use on human skeletal muscle. Histochem. J. 21, 545–555 (1989).
- Murphy J. L. et al. Cytochrome c oxidase-intermediate fibres: importance in understanding the pathogenesis and treatment of mitochondrial myopathy. Neuromuscul Disord 22, 690–698 (2012).
- Cree L. M. et al. A reduction of mitochondrial DNA molecules during embryogenesis explains the rapid segregation of genotypes. Nat Genet 40, 249–254 (2008).
- Pfaffl M. W., Horgan G. W. & Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30, 1–10 (2002).
Source: PubMed